103 related articles for article (PubMed ID: 11391855)
1. Population pharmacokinetic modeling and model validation of a spicamycin derivative, KRN5500, in phase 1 study.
Takama H; Tanaka H; Sudo T; Tamura T; Tanigawara Y
Cancer Chemother Pharmacol; 2001 May; 47(5):404-10. PubMed ID: 11391855
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic study of KRN5500, a spicamycin derivative, for patients with advanced solid tumors.
Yamamoto N; Tamura T; Kamiya Y; Ono H; Kondoh H; Shirao K; Matsumura Y; Tanigawara Y; Shimada Y
Jpn J Clin Oncol; 2003 Jun; 33(6):302-8. PubMed ID: 12913085
[TBL] [Abstract][Full Text] [Related]
4. A phase I clinical trial of spicamycin derivative KRN5500 (NSC 650426) using a phase I accelerated titration "2B" design.
Gadgeel SM; Boinpally RR; Heilbrun LK; Wozniak A; Jain V; Redman B; Zalupski M; Wiegand R; Parchment R; LoRusso PM
Invest New Drugs; 2003 Feb; 21(1):63-74. PubMed ID: 12795531
[TBL] [Abstract][Full Text] [Related]
5. [Spicamycin derivative].
Mizumura Y
Nihon Rinsho; 2006 Feb; 64(2):322-8. PubMed ID: 16454188
[TBL] [Abstract][Full Text] [Related]
6. In vitro interactions of a new derivative of spicamycin, KRN5500, and other anticancer drugs using a three-dimensional model.
Kanzawa F; Nishio K; Fukuoka K; Sunami T; Saijo N
Cancer Chemother Pharmacol; 1999; 43(5):353-63. PubMed ID: 10100589
[TBL] [Abstract][Full Text] [Related]
7. Manual and automatic extraction and high-performance liquid chromatographic determination of a spicamycin derivative, KRN5500, in rat plasma.
Yoshioka E; Morino M; Tanaka H; Shinkai H
J Chromatogr B Biomed Sci Appl; 1997 Apr; 691(2):371-5. PubMed ID: 9174273
[TBL] [Abstract][Full Text] [Related]
8. Stability and performance of a population pharmacokinetic model.
Ette EI
J Clin Pharmacol; 1997 Jun; 37(6):486-95. PubMed ID: 9208355
[TBL] [Abstract][Full Text] [Related]
9. The novel anticancer drug KRN5500 interacts with, but is hardly transported by, human P-glycoprotein.
Takara K; Tanigawara Y; Komada F; Nishiguchi K; Sakaeda T; Okumura K
Jpn J Cancer Res; 2000 Feb; 91(2):248-54. PubMed ID: 10761713
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
[TBL] [Abstract][Full Text] [Related]
11. Spicamycin and KRN5500 induce apoptosis in myeloid and lymphoid cell lines with down-regulation of bcl-2 expression and modulation of promyelocytic leukemia protein.
Zhang WJ; Ohnishi K; Yoshida H; Pan L; Maksumova L; Muratkhodjaev F; Luo JM; Shigeno K; Fujisawa S; Naito K; Nakamura S; Shinjo K; Takeshita A; Ohno R
Jpn J Cancer Res; 2000 Jun; 91(6):604-11. PubMed ID: 10874212
[TBL] [Abstract][Full Text] [Related]
12. A spicamycin derivative (KRN5500) provides neuropathic pain relief in patients with advanced cancer: a placebo-controlled, proof-of-concept trial.
Weinstein SM; Abernethy AP; Spruill SE; Pike IM; True Kelly A; Jett LG
J Pain Symptom Manage; 2012 Apr; 43(4):679-93. PubMed ID: 21983265
[TBL] [Abstract][Full Text] [Related]
13. A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
van den Bongard HJ; Mathôt RA; van Tellingen O; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2002 Jul; 50(1):16-24. PubMed ID: 12111107
[TBL] [Abstract][Full Text] [Related]
14. The effects of KRN5500, a spicamycin derivative, on neuropathic and nociceptive pain models in rats.
Abdi S; Vilassova N; Decosterd I; Feroz N; Borsook D
Anesth Analg; 2000 Oct; 91(4):955-9. PubMed ID: 11004056
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of a spicamycin derivative, KRN5500, and its active metabolite in tumor cells.
Kamishohara M; Kawai H; Sakai T; Isoe T; Hasegawa K; Mochizuki J; Uchida T; Kataoka S; Yamaki H; Tsuruo T
Oncol Res; 1994; 6(8):383-90. PubMed ID: 7894087
[TBL] [Abstract][Full Text] [Related]
16. Antineuropathic effects of the antibiotic derivative spicamycin KRN5500.
Borsook D; Edwards AD
Pain Med; 2004 Mar; 5(1):104-8. PubMed ID: 14996243
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effect of a spicamycin derivative, KRN5500, on the growth of hepatic metastasis of human colon cancer-producing tissue polypeptide antigen.
Kamishohara M; Kawai H; Sakai T; Uchida T; Tsuruo T; Otake N
Cancer Chemother Pharmacol; 1996; 38(6):495-8. PubMed ID: 8823489
[TBL] [Abstract][Full Text] [Related]
18. KRN5500, a spicamycin derivative, exerts anti-myeloma effects through impairing both myeloma cells and osteoclasts.
Miki H; Ozaki S; Nakamura S; Oda A; Amou H; Ikegame A; Watanabe K; Hiasa M; Cui Q; Harada T; Fujii S; Nakano A; Kagawa K; Takeuchi K; Yata K; Sakai A; Abe M; Matsumoto T
Br J Haematol; 2011 Nov; 155(3):328-39. PubMed ID: 21902681
[TBL] [Abstract][Full Text] [Related]
19. KRN5500, a novel antitumor agent, induces apoptosis or cell differentiation in HL-60 cells.
Kawasaki K; Murakami T; Ita M; Sasaki K; Furukawa S
Cytometry; 2000 Mar; 39(3):211-6. PubMed ID: 10685078
[TBL] [Abstract][Full Text] [Related]
20. [Population pharmacokinetic modeling and evaluation of propofol from multiple centers].
Ye HB; Zheng H; Zhang XA; Chi XJ; Chen WY; Xu JG; Li JH; Rui JZ
Yao Xue Xue Bao; 2010 Dec; 45(12):1550-8. PubMed ID: 21351496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
